Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel
OTCMKTS:TRUMY

Terumo 2/13/2026 Earnings Report

Terumo logo
$12.61 +0.01 (+0.08%)
As of 03:58 PM Eastern
ProfileEarnings HistoryForecast

Terumo EPS Results

Actual EPS
$0.15
Consensus EPS
$0.15
Beat/Miss
Missed by -$0.00
One Year Ago EPS
N/A

Terumo Revenue Results

Actual Revenue
$1.94 billion
Expected Revenue
$1.82 billion
Beat/Miss
Beat by +$122.63 million
YoY Revenue Growth
N/A

Terumo Announcement Details

Quarter
Date
2/13/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Terumo's next earnings date is estimated for Friday, May 15, 2026, based on past reporting schedules.

Conference Call Resources

Terumo Earnings Headlines

Terumo Corporation (TRUMY) Q3 2026 Earnings Call Transcript
February 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4870046-terumo-corporation-trumy-q3-2026-earnings-call-transcript
Terumo Corporation (TRUMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
January 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4859067-terumo-corporation-trumy-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
May 5 at 1:00 AM  |  Weiss Ratings (Ad)
Terumo Corporation (TRUMY) Q2 2026 Earnings Call Transcript
November 12, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4842354-terumo-corporation-trumy-q2-2026-earnings-call-transcript
OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation
October 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/30/3177295/0/en/organox-completes-acquisition-by-terumo-corporation-to-advance-the-future-of-organ-transplantation.html
Terumo Acquiring Its Way Into The Intriguing Organ Donation Market
August 28, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4817439-terumo-stock-acquiring-way-into-intriguing-organ-donation-market
See More Terumo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Terumo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Terumo and other key companies, straight to your email.

About Terumo

Terumo (OTCMKTS:TRUMY) Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags. Through its Terumo BCT subsidiary, the company also provides apheresis, blood component management and cell therapy technologies used by blood banks, transfusion services and cell-therapy developers. Terumo’s portfolio emphasizes single-use medical devices and clinically oriented systems designed to improve procedural outcomes and patient safety.

Founded in the early 20th century and headquartered in Tokyo, Terumo has grown into a multinational supplier with operations and sales networks across Asia, the Americas and Europe. The company distributes products globally through a combination of regional subsidiaries, direct sales teams and distribution partners, serving hospitals, specialty clinics and blood centers. As a publicly listed Japanese corporation, Terumo also maintains an American depositary receipt (ADR) listing that enables trading on overseas markets.

View Terumo Profile
Earnings Tools